Added to YB: 2026-10-08
Pitch date: 2026-10-04
IRD [bullish]
Opus Genetics, Inc.
-11.38%
current return
Author Info
No bio for this author
Company Info
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Market Cap
$364.4M
Pitch Price
$4.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
-6.17
P/E
-3.39
EV/Sales
31.63
Sector
Biotechnology
Category
special_situation
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Opus Genetics, Inc.
IRD (update): Opus Genetics’ first value driver is the October 17, 2026 PDUFA for phentolamine 0.75% in presbyopia, which could bring a milestone and reassessment of partnered economics; Viatris owns exclusive U.S. commercialization rights, while Opus is eligible for up to $130M in additional milestones and tiered royalties. Longer-term value could come from inherited-retinal-disease gene therapies if safety and efficacy mature, with risks including regulatory delay, a complete response letter, a limited label, weak adoption and disappointing license value realization.
Read full article (1 min)